SAB Biotherapeutics, Inc. (NASDAQ:SABS) Sees Large Decline in Short Interest

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the target of a significant decrease in short interest in March. As of March 31st, there was short interest totalling 92,700 shares, a decrease of 19.4% from the March 15th total of 115,000 shares. Currently, 1.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 107,200 shares, the days-to-cover ratio is currently 0.9 days.

SAB Biotherapeutics Trading Down 4.6 %

Shares of SABS stock opened at $1.37 on Tuesday. SAB Biotherapeutics has a 1 year low of $1.00 and a 1 year high of $5.01. The company has a market cap of $12.72 million, a PE ratio of -0.38 and a beta of 0.52. The stock’s 50 day simple moving average is $1.54 and its two-hundred day simple moving average is $2.65. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.69 and a quick ratio of 3.69.

SAB Biotherapeutics (NASDAQ:SABS) last announced its earnings results on Friday, March 28th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.07). The company had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.12 million. SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. Research analysts predict that SAB Biotherapeutics will post -3.69 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of SAB Biotherapeutics in a research note on Tuesday, April 1st. Chardan Capital decreased their price target on shares of SAB Biotherapeutics from $25.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, April 1st. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $11.40.

Institutional Trading of SAB Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Northern Trust Corp acquired a new stake in shares of SAB Biotherapeutics in the fourth quarter worth approximately $43,000. Silver Oak Securities Incorporated purchased a new position in shares of SAB Biotherapeutics during the first quarter worth $30,000. Diadema Partners LP purchased a new stake in SAB Biotherapeutics during the fourth quarter worth about $114,000. Geode Capital Management LLC grew its stake in shares of SAB Biotherapeutics by 18.8% in the fourth quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock worth $307,000 after acquiring an additional 12,692 shares in the last quarter. Finally, HB Wealth Management LLC boosted its holdings in SAB Biotherapeutics by 118.6% in the fourth quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock valued at $982,000 after purchasing an additional 128,800 shares during the period. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.